Vedolizumab

Vedolizumab is a new class of genetically engineered medications, ENTYVIO® is the first and only gut-selective biologic therapy with no known systemic immunosuppressive effects and approved for use in Canada in adult moderately to severely active CD and UC patients who have had an inadequate response with, loss of response to, or were intolerant to immunomodulators or a tumour necrosis factor-alpha (TNFα) antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.

You can review a video highlighting the mechanism of Vedolizumab ENTYVIO® action below:

Additional documents:

• ENTYVIO® Startup sheet
• VEDEOLIZUMAB Patient Information sheet

References